Latest / Stock Movers / Paycom Rallies, Fortinet Disappoints, Lilly Falls
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
- 0:08Speaker 2: The Stock Movers Report, your roundup of companies making moves
- 0:12Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
- 0:16Speaker 1: All right, I'm Carol Masser along with Nora Melinda here
- 0:20Speaker 1: on Bloomberg Businessweekdaily. We want to get into some of
- 0:23Speaker 1: the stocks on the move today. Here to do that
- 0:25Speaker 1: is Bloomberg News Deputy team leader for US Equities Jess
- 0:28Speaker 1: Metten in our studio. All right, good to have you here.
- 0:31Speaker 1: So let's start with Paycom.
- 0:33Speaker 3: What are we seeing?
- 0:34Speaker 4: So this is a software cloud company that works more
- 0:37Speaker 4: in the payroll and HR space, so some of its
- 0:40Speaker 4: rivals are Workday. So Paycom is in the S and
- 0:43Speaker 4: P five hundred. The ticker symbol is PAYC. So it
- 0:47Speaker 4: actually jumped as much as twelve percent earlier this morning,
- 0:50Speaker 4: gave up some of those gains, but still actually up
- 0:53Speaker 4: close to about four percent right now. So I wanted
- 0:55Speaker 4: to point that out just because it did boost its
- 0:58Speaker 4: full year revenue forecast. And this does tie to AI
- 1:02Speaker 4: because it was driven by artificial intelligence demands. So obviously
- 1:06Speaker 4: not just when you think of those tech and growth
- 1:08Speaker 4: companies when it's an AI story, but also when it
- 1:10Speaker 4: comes to payroll in HR software providers there, and I
- 1:14Speaker 4: wanted to point out too, because when you're looking at
- 1:16Speaker 4: that stock, it actually was trading around right now close
- 1:19Speaker 4: to two hundred and thirty one dollars. It got close
- 1:21Speaker 4: to resistance from a technical perspective around two forty three
- 1:25Speaker 4: earlier today, So that was actually dating back to its
- 1:28Speaker 4: December high. So that might be some of the reasons
- 1:30Speaker 4: why we saw it pulled back a little bit there.
- 1:32Speaker 4: But a in our function, if you want to look
- 1:34Speaker 4: at the cell side targets there there's four buys, fifteen
- 1:36Speaker 4: holes and zero cells.
- 1:37Speaker 3: Why I was about the number one gainer in the
- 1:39Speaker 3: S ANDP it why it was, Yes, it was and
- 1:42Speaker 3: so and now it's I had to talk to because
- 1:45Speaker 3: I didn't recognize the ticker. And again these software companies
- 1:49Speaker 3: that are outperformed.
- 1:50Speaker 4: It was added to the S and P five hundred
- 1:52Speaker 4: actually a little bit more than five years ago in
- 1:54Speaker 4: January of twenty twenty. So it is indeed in the
- 1:56Speaker 4: major indecks of about fourteen percent so far this year.
- 2:00Speaker 4: What else are you looking at? So I'm going to
- 2:02Speaker 4: move over to the decliners today. It's the two worst
- 2:04Speaker 4: performers in the S and P five hundred. So we'll
- 2:06Speaker 4: start off first with Fortinet FTTNT is this ticker symbol
- 2:11Speaker 4: on this down twenty five percent, so this would be
- 2:14Speaker 4: on pace if it holds through the clothes. It's worst
- 2:16Speaker 4: day since November two thousand and nine, so when you're
- 2:20Speaker 4: thinking about cybersecurity, and also some of its peers really
- 2:24Speaker 4: balche no exactly so to go that far back, and
- 2:28Speaker 4: it's the worst performer in the NAZAQ one hundred as well.
- 2:31Speaker 4: So it gave an update to its firewall refresh cycle.
- 2:34Speaker 4: The problem was it wasn't as good as what cell
- 2:38Speaker 4: side strategists, shareholders and investors were anticipating. So really it
- 2:42Speaker 4: was supposed to be this opportunity to update or renew
- 2:44Speaker 4: that type of IT infrastructure, but that unfortunately the product
- 2:48Speaker 4: growth the estimates were declining there and so that's why
- 2:51Speaker 4: you're seeing it getting pummeled on the cell side though,
- 2:53Speaker 4: William Blair analysts saying they're not seeing strong product revenue
- 2:56Speaker 4: growth and billings materialize right now. And then of course
- 3:00Speaker 4: Bloomberg Intelligence Zone man Deep Sing was pouring out as
- 3:03Speaker 4: well that fortnete is unlikely to see any big profit
- 3:06Speaker 4: lived from its product refresh cycle. So you all are
- 3:09Speaker 4: seeing those piers like data dog. Of course, one of
- 3:11Speaker 4: Tom King's favorite d dog is the ticker symbol and
- 3:13Speaker 4: that down more than four percent. And then also looking
- 3:16Speaker 4: at Palo Alto Networks pa n W is the ticker
- 3:20Speaker 4: down four percent as well.
- 3:21Speaker 1: Let's talk Eli Lily ticker l wyse, I mean.
- 3:24Speaker 4: Her green blaker.
- 3:27Speaker 1: I know, I know, there she goes.
- 3:29Speaker 4: I know, I still unfortunately poured the corel of lotter
- 3:31Speaker 4: on it, but I had to point out because.
- 3:33Speaker 1: It's such a tear a year after year, but a
- 3:37Speaker 1: different tone today.
- 3:38Speaker 4: And this is the second worst performer in the S
- 3:40Speaker 4: and P five hundred before, behind a Fortnite. So when
- 3:43Speaker 4: you're looking at this stock, the ticker symbol ll Y
- 3:46Speaker 4: down fourteen percent on pace and I had a double
- 3:49Speaker 4: check this on piece of its worst day since August
- 3:51Speaker 4: two thousand. Is pretty wild there. So on the flip
- 3:54Speaker 4: side of that, if you look at its rival Novo
- 3:56Speaker 4: nordis if the US listed shares here, nvos the tickers
- 3:59Speaker 4: and actually up seven percent because they're going to benefit
- 4:02Speaker 4: from this. So if you're looking at Eli Lilly, of
- 4:05Speaker 4: course it's outlook for twenty twenty five top quarterly estimates.
- 4:09Speaker 4: If you're looking at those types of drugs that we
- 4:10Speaker 4: talk about so much with Montero and zep Bound, those
- 4:13Speaker 4: sales are actually soaring. But unfortunately it was this study
- 4:16Speaker 4: that they were doing that overshadowed some of the optimism
- 4:19Speaker 4: when it comes to earnings. So it's experimental pill that
- 4:22Speaker 4: helped patients actually shed roughly about eleven percent of their
- 4:26Speaker 4: body weight in a late stage study. It just wasn't
- 4:28Speaker 4: as good and as close to what its rival Novodortis
- 4:31Speaker 4: had done. That's why you ended up seeing that pumbled.
- 4:33Speaker 4: So you're seeing those two stocks diverge and go in
- 4:35Speaker 4: different directions from needles to pills.
- 4:37Speaker 3: Right, that's the new transition they're hoping.
- 4:40Speaker 1: They're hopefully, you know, those having its own problems as well.
- 4:43Speaker 1: I mean, it's just as we kind of transition through.
- 4:47Speaker 2: The stock mover's report from Bloomberg Radio. Check back with
- 4:51Speaker 2: us throughout the day for the latest roundup of companies
- 4:54Speaker 2: making news on Wall Street and for the latest market
- 4:57Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 5:02Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 5:05Speaker 2: the Bloomberg Business app